Atrial Fibrillation Management Approach

Anticoagulation Strategy

The American College of Cardiology recommends direct oral anticoagulants (DOACs) as the first-line anticoagulation choice for patients with atrial fibrillation and prior stroke/TIA or CHA₂DS₂-VASc score ≥2, with apixaban, rivaroxaban, dabigatran, or edoxaban being preferred over warfarin 1, 2, 3
The American Heart Association suggests calculating the CHA₂DS₂-VASc score to determine stroke risk, with 1 point each for congestive heart failure, hypertension, diabetes, vascular disease, age 65-74 years, and female sex, and 2 points each for age ≥75 years and prior stroke/TIA/thromboembolism 1, 2, 3
For patients with a CHA₂DS₂-VASc score ≥2 (men) or ≥3 (women), oral anticoagulation is mandatory, according to the American College of Cardiology 2, 3

The American College of Cardiology recommends beta-blockers or non-dihydropyridine calcium channel antagonists as first-line agents for rate control, with beta-blockers preferred for controlling both heart rate and blood pressure without peripheral edema risk 8
The European Society of Cardiology suggests a lenient rate control target (resting heart rate <110 bpm) for asymptomatic patients with preserved left ventricular systolic function, and a strict rate control target (resting heart rate <80 bpm) for symptomatic patients 8, 5

The American Heart Association recommends anticoagulation with warfarin (INR 2.0-3.0) or DOAC for ≥3 weeks before and ≥4 weeks after cardioversion for AF or atrial flutter ≥48 hours duration or unknown duration, regardless of CHADS₂ score 8
The American College of Cardiology suggests AV nodal ablation with permanent ventricular pacing as a reasonable option when pharmacological therapy is inadequate and rhythm control is not achievable, but only after prior attempts at medication-based rate control 8

The American College of Cardiology recommends assessing renal function before initiating any DOAC and reevaluating at least annually, with dose adjustments as needed based on renal function 1, 5, 3, 7
The European Society of Cardiology suggests that impaired renal function is a potent independent predictor of stroke and systemic embolism, second only to prior stroke/TIA 8
The American Heart Association recommends strict blood pressure control (<140/90 mmHg) when anticoagulation is initiated to minimize bleeding risk 10